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At the boundaries of food and medicine: the genesis and transformation of 
the “functional food” markets in France and Europe1 
  
 
Abstract 
Functional foods have swept across France and Europe since the late 1980s. Margarines en-
riched with omega 3 or phytosterols, yoghurts enriched with bifidus or vitamin-rich food sup-
plements… these foods with health claims have reopened the boundary erected over the course 
of the twentieth century between the markets for medicines, whose primary function is to treat 
the sick, and those for foods, whose primary function is to meet the nutritional needs of healthy 
people. They thus raise many issues for regulators, producers, distributors and consumers. Are 
they health products that can usefully contribute to the prevention of chronic diseases or mar-
keting manipulations that are not of any health interest? Should they be regulated and marketed 
as drugs, as food or as a separate category? 
Drawing on significant contributions in economic history and sociology, this article analyzes 
the consequences of the classification of these products as medicines, foods or dietary supple-
ments on their valuation and the structure of their markets. It also focuses on the boundary 
work in which industry and regulatory actors engage in order to “(re)classify” these products, 
and thereby “(re)structure” the markets in which they circulate. 
The first part of the article describes the process that led France to establish a boundary be-
tween the previously intertwined markets for medicines and foods over the course of the twen-
tieth century, which has been blurred by the appearance of functional foods since the beginning 
of the 1980s. The second part deals with the efforts of French and European regulatory author-
ities and industry actors to renegociate these boundaries between the markets for medicines 
and foods bearing nutritional and health claims. We conclude this second part with a discussion 
of the consequences of this reframing for the reorganization of markets and the reevaluation of 
the health benefits and commercial advantages of these products. 
 
Keywords: Market Regulation; Classification and Valuation; Boundary; Health Claim; Func-
tional Food; Medicine.   
                                                 
1 This working paper is the result of collective research on the construction of a European market for probiotics. 
The authors would like to thank Henri Bergeron and Patrick Castel, who participated in this research and have 
extensively engaged with earlier versions of this article. This project has benefited from the support of the ANR 
and public funding through the future investments program as part of the LIEPP Labex (Laboratoire Interdiscipli-
naire d’Evaluation des Politiques Publiques, Sciences Po. Paris) ANR 11 LABX0091, ANR 11 IDEX000502. 
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Introduction 
In an article published in the journal of the European Society for Clinical Nutrition and 
Metabolism, Diana Cardenas (2013) examined the widespread quotation of a phrase falsely 
attributed to Hippocrates (or to what is known as the Hippocratic Corpus) – “let food be thy 
medicine and medicine be thy food” – in medical journal articles over the last thirty years.2 For 
the author, use of this invented quotation leads to an essential misconception about Hippocratic 
medicine, which established a clear difference between food –  which was to be assimilated by 
the body – and medicine – which was to change the body without being assimilated by it. 
However, as she underlines, these invocations of Hippocratic thought aim less at increasing our 
understanding of classical medicine than “at proving the role of nutrition in different fields such 
as cancer, epigenetics, immunology, disease prevention or chronic diseases [… or] validat[ing] 
and legitimat[ing] scientifically and ethically the current concepts of nutraceuticals or 
functional foods from Antiquity. However, by attributing pharmacological properties to foods, 
authors are confusing both food and medicine” (Cardenas, 2013, p.261; our italics). 
This “confusion between food and medicine” is characteristic of the 1990s and 2000s, which 
saw a proliferation of products positioned explicitly at the intersection of medicine (in that they 
claim “health benefits”) and food (in terms of the industrial sector in which they are placed for 
regulatory purposes and from which their producers often come): the polyunsaturated fatty 
acids (omega-3 and 6) and phytosterols used in certain margarines and oils to reduce the risk of 
coronary heart disease; the probiotics and prebiotics3 added to dairy products to facilitate 
digestion and protect against seasonal illnesses; or the vitamins and fiber contained in cereals 
and “energy” drinks to compensate for deficiencies due to unbalanced diets. The terms and 
definitions used for these products – “nutraceuticals” (portmanteau combining “nutrient” and 
“pharmaceuticals”), “functional foods”, “healthy foods”, or “droods” (portmanteau combining 
“drugs” and “food”) – proliferated at the beginning of the 1990s, signaling the diverse efforts 
and uncertainties on the part of producers and public regulators, as well as medical and scientific 
institutions, to place these products in a clear healthcare, regulatory and marketing category 
(Veyssière, 2007; Grossman, 2008). These initiatives continued to multiply until the adoption, 
in 2006, of a European regulation (CE 1924-2006) establishing norms for product labelling of 
nutritional and health claims, the implementation of which had significant consequences for the 
organization of these markets. 
This study seeks precisely to analyze the dynamics of creation and institutionalization of these 
markets at the boundary of medicine and food, in France (and Europe) since the beginning of 
the 1990s. Drawing on significant contributions in economic history and sociology (Bowker 
                                                 
2 We also did a search for this phrase in the mainstream francophone press (using the Factiva search engine) and 
found roughly forty uses during the period from 1998 to 2016. As in the scientific articles studied by Diana Car-
denas (2013), these press articles often discuss the links between food and health and many of them deal more 
specifically with “functional foods,” “healthy foods” or “nutraceuticals.” 
3 Probiotics were defined in 2001 as “a living micro-organism which, when introduced in sufficient quantity, pro-
duced beneficial health effects for the host.” The principal components of probiotics used in the industry are lac-
tobacillus and bifidobacterium. Prebiotics are fiber compounds that serve as substrates for probiotic bacteria and 
thus promote their growth and development to the detriment of other bacteria. 
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and Star, 2000; Musselin and Paradeise, 2002; Stanziani, 2003; Beckert and Musselin, 2013), 
we aim to demonstrate the ways in which the classification of these products as medicines, 
foods, or dietary supplements, and the evaluation of their health benefits and risks, have major 
consequences for the organization of their markets and the value attributed to them. “Functional 
foods” constitute particularly interesting objects of study for exploring the links between 
processes of market healthicization4, which seek to turn markets into instruments for the 
promotion of public health, and the marketization of health, which aim to make public health 
into a means of organizing and developing markets. Indeed, these products have reopened the 
boundaries erected over the course of the twentieth century between the markets for medicines, 
whose primary function is to treat the sick, and those for foods, whose primary function is to 
meet the nutritional needs of healthy people. The present contribution aims to interrogate the 
boundary work (Gieryn, 1983) in which industry and regulatory actors engage in order to 
“(re)classify” these products, and thereby “(re)structure” the markets in which they circulate. 
The structure of this article is heavily inspired by the concept of “framing/overflowing” 
developed by Michel Callon (1998) to think about processes of innovation. Thus, the first part 
describes the process of “framing”, which led France to separate the markets for medicines and 
foods over the course of the twentieth century, before turning to the “overflowing” represented 
by the appearance of functional foods since the beginning of the 1980s. The second part deals 
with the efforts of French and European regulatory authorities and industry actors to “reframe” 
these overflowings through a “renegotiation” of the boundaries between the markets for 
medicines and foods (or dietary supplements) bearing nutritional and health claims. We 
conclude this second part with a discussion of the consequences of this reframing for the 
reorganization of markets and the reevaluation of the health benefits and commercial 
advantages of these products.5  
 
I. A porous boundary between medicine and food: the creation of in-
terstitial functional food markets 
The introduction of the first yogurts with “active bifidus” and the first “omega-3-enriched” 
margarines at the end of the 1980s set off intense media, but also legal, controversies between 
industry actors, consumer organizations and regulatory authorities. While industry actors drew 
on scientific research to claim health benefits for their products, and to thereby distinguish them 
from the competition, consumer organizations and regulatory authorities were highly skeptical 
of the scientific legitimacy and health advantages of these claims. Was health not the exclusive 
domain of the pharmaceutical field? To understand these controversies, it is necessary to return 
to the processes at work over the course of the twentieth century which gradually constructed 
an impermeable boundary between medicine, intended to heal or prevent illness, and food, 
whose health benefits were limited to providing for people’s nutritional needs. This boundary 
                                                 
4 The term “healthicization” is borrowed from Didier Fassin (1998), who defines it as a double process of medi-
calization (consisting in the framing of a social problem in the language of public health) and politicization (con-
sisting in the placing of this social problem on the agenda as a problem of public health). For an argument similar 
to ours, see also Steiner and Trespeuch (2014).  
5 This study is based in part on a review of the francophone press over the period 1997-2016, conducted using the 
Factiva database, and in part on analyses of the legal norms and guidelines produced by French and European food 
regulatory agencies. 
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did not only separate categories of products but also ways of commercializing and promoting 
them. The proliferation of functional foods in the 1990s and 2000s had the effect of blurring 
this boundary, allowing for the creation of new interstitial markets, which belonged neither to 
the “pure” medicine market, nor to the market for “simple” foods, but which played precisely 
on the porosity of the boundary between the two.  
1.1. From the insistence on a boundary between medicine and food… 
That hybrid “functional foods” proved problematic at the end of the twentieth century might 
seem odd, given the fact that the histories of medicine and food were very much entangled until 
the middle of the century. Indeed, numerous articles on the history of pharmacy highlight the 
therapeutic virtues that have long been projected onto many foodstuffs: bread, blessed or 
otherwise, was thought to combat the plague, eye disease and even rabies; chocolate was 
indicated for the treatment of “chest and stomach pain, fever, ‘fragile nerves’, biliary 
inflammation, colds, dysentery, diarrhea, cholera, etc., not to mention its reputation as a 
stimulant and aphrodisiac, blacklisted by the church but employed by royal mistresses” 
(Paternotte and Labrude, 2003). Certain staple foods were marketed from the outset as 
medicines. This was, for example, the case for the tomato, which was promoted at the beginning 
of the nineteenth century by European doctors in pill form for the treatment of diarrhea, 
gallbladder attacks, dyspepsia, etc., before becoming a popular vegetable known only for its 
richness in vitamins (Smith, 1991). This was also the case for Bulgarian yogurt, sold in France 
at the beginning of the twentieth century in pharmacies and creameries where its benefits for 
intestinal disorders and the immune system were celebrated, in keeping with the work of the 
Pasteurians, in particular Elie Metchnikoff. Aram yogurt was sold in the 1910s with the claim 
that it was “recommended by Prof. Metchnikoff of the Pasteur Institute for people with delicate 
constitutions and as a dessert” and was accompanied by a document in which the illustrious 
professor stated: “I have eaten and analyzed Aram yogurt. It is not harmful to health. On the 
contrary, it contains lactic bacteria which are useful for our bodies.”6 The companies that market 
probiotics today make regular reference to “pioneering” scientists and producers in order to 
recall the historical pedigree of the knowledge on which their “innovations” are based and to 
underscore, by way of contrast, the “timorousness” of contemporary health regulators vis-à-vis 
their products. But this ellipsis also sheds light on the processes through which the twentieth 
century led to a separation of the regulatory, industrial and commercial spaces in which foods 
and medicines circulated. 
These processes of separation impacted medicines first and foremost, steadily leading to the 
legal definition of these products around their therapeutic purposes (treating or preventing 
illness) and their pharmacological, immunological or metabolic properties (restoring, correcting 
or modifying bodily functions) (Chauveau, 2005). The definition of a medicine adopted in 1965 
at the European level and transposed into French law by the administrative order of 23 
September 1967 (reproduced in article L.5111-1 of the Public Health Code) read as follows: 
“Any substance or composition presented as possessing preventive or curative properties with 
regard to human or animal diseases, as well as all products that can be administered to humans 
with the aim of establishing a medical diagnosis or to restore, correct or modify their bodily 
                                                 
6 Source: https://www.philippe-burlet.fr/famille/aram-deukmedjian/yaourt/  
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functions.” This definition thus aims to establish a boundary between medicines – whose 
alleged function is to treat the sick or act on bodily functions, and for which a balance between 
health benefits and risks needs to be established – and other products, which might contribute 
to the “maintenance of health” in addition to their other functions but which must not represent 
any health risks.  
Taking off from this definition, the regulatory boundary between medicines and other products 
(notably foods) was steadily extended to all dimensions of the market. At a primary level, the 
growth of regulatory pressure, in the wake of the health scandals that punctuated the century, 
thus led to the strict upstream control by public authorities of these products through procedures 
for market authorization delivered by a competent health authority (the pharmacy division of 
the ministry of health until 1993, the French Medicines Agency or the European Medicines 
Agency (EMA) after that date7) and based on an expert evaluation of benefits and risks 
(Chauveau, 1999). At a second level, doctors and pharmacists fought to obtain and retain an 
exclusive monopoly on the prescription and delivery of these products. They thus constitute 
essential intermediaries between supply and demand, and accordingly occupy a central position, 
as much for the regulation of competition as for the promotion of products, through their choice 
of prescriptions. At a third level, the industrialization of extraction and production techniques 
of active ingredients and the optimization of research and development, with the 
institutionalization of screening methods and randomized, double-blind clinical trials, 
encouraged the autonomy of the pharmaceuticals industry around a model of product promotion 
based on the demonstration of therapeutic added value (Marks, 1997; Chast, 2002; 
Timmermans and Berg, 2010). The translation of the latter into commercial added value relies 
on the mobilization of patents (enabling the “protection” of the original against the copy), on 
the one hand, and on the development of public healthcare insurance, on the other, which led 
to the adoption of lists of approved medicines, distinguishing those considered useful or 
indispensable for public health, and thus covered by the public healthcare insurance, from those 
judged unnecessary or superfluous and therefore not covered and left to the individual. The 
market for these medicines at the beginning of the 1990s was thus characterized by a mode of 
regulation, distribution, industrial development, and commercialization that constituted so 
many barriers to entry for products and firms that have not run this gauntlet. 
Food products also became objects of regulation, in particular with the law of 1905 on fraud 
and counterfeit, which structured the regulation of this sector in France until the beginning of 
the 1990s. According to Alessandro Stanziani (2005), the primary objective of this regulation 
was not the protection of consumer safety but the regulation of competition among producers. 
The public health arguments were invoked to legitimate the prohibition of a production process. 
The use of a food or food additive was accepted or rejected based on their capacity to protect 
the interests of the French dominant producers from competition by foreign producers 
(Stanziani, 2005). This hypothesis emerges most strongly in the study he conducted with 
Laetitia Piet and Jérôme Bourdieu on the French meat market. From the trichinosis and bovine 
tuberculosis of the end of the nineteenth century to the mad cow crisis in the 1980s and 1990s, 
“questions of food safety in the meat industry reflect the hierarchy between the disciplining of 
                                                 
7 The French Medicines Agency (AFSSAPS or ANSM since 2012) was created in 1993. The French Food Safety 
Agency (AFSSA) was created in 1999 and then merged with the Environment and Labour Health Safety Agency 
(AFSSET) in 2010 to become the French Food, Environment and Labour Health Safety (ANSES).  
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competition and the protection of public health” (Bourdieu, Piet and Stanziani, 2004, p.155). 
But what is most interesting about this history of food safety is that it implicitly reveals a second 
hierarchy, one between security of supply (the objective being to increase the quantity of food 
produced to “meet the needs” of the population) and food safety (the objective being to ensure 
that the consumption of food does not present health risks). Thus, any possible health benefits 
from diet were conceived throughout the twentieth century in terms of the absolute quantity of 
“nutrients”, of carbohydrates and fats, supplied (underpinned by a caloric approach). While the 
regulation of medicine gradually stabilized around an assessment of the balance between health 
benefits and risks, the regulation of food sought to strike a balance between these health risks 
and other benefits not purely health-related. A second distinguishing element concerns the 
regulation of the market itself. While the market for medicines developed from the 1960s 
around the marketing authorization procedure, regulation of the food market rested more on the 
control of “claims,” with the law of 1905 introducing the notions of “fraud,” “counterfeit,” and 
“false advertising” (Frohlich, 2017).  
Thus, at the end of the 1980s, medicine and food seemed to be separated by an impermeable 
boundary, bearing not only on the definition of their characteristics but also on modes of 
organization and commercialization. The development of functional foods fractured this 
boundary.  
1.2.  … to its challenge by functional foods 
“Since the appearance of bifidus yogurt in the mid-1980s, ‘healthy’ foods have proliferated like 
biblical loaves in the large supermarkets. Fruit juices, yogurts and cereals rich in vitamins (A, 
E, calcium), ‘bifido-fiber’ sugar for intestinal regularity, milk pasta for child growth, eggs 
‘enriched with omega-3 fatty acids’, etc. The list gets longer every day. According to the 
marketing consulting firm XTC, 19% of new food products launched each year in France, and 
22% globally, display concepts related to health.”8 This press article from 2001 highlights the 
magnitude of the wave that washed over France and European markets at the beginning of the 
1990s. But we should also add to this already considerable list of “healthy foods” the dietary 
supplements (e.g. Oenobiol® and Bion3®), meal replacements (e.g. Slim Fast®) and dietetic 
products (e.g. products marketed by Bjorg), medicinal plants available outside pharmacies and 
phytotherapy (e.g. products marketed by Arkopharma and Fenioux laboratories), and finally 
oral care cosmetics (e.g. the Inneov line developed by L’Oréal), that fill the aisles of pharmacies 
and supermarkets, when they are not sold directly by mail order. 
Bernhard Kitous (2003) has suggested the following definition for functional foods (inspired 
by the Canadian definition for health products): “all products, processed or raw, intended for 
human consumption, for which a claim of ‘health maintenance benefits’ is made. It might be a 
complete food, an ingredient (nutraceutical) or combination of ingredients integrated into a 
single food product, or a distinct product like a meal substitute, dietary supplement, or staple 
food supplement” (Kitous, 2003, p.20). These different products all share a common claim to 
“health maintenance benefits,” thus placing them outside the category of “staple foods,” which 
                                                 
8 Laurent Flallo, “Le potentiel de croissance du marché des aliments santé demeure incertain,” Les Echos, 12 
December 2001. 
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do not offer any health “added value,” but also falling short of the category of medicine since 
they cannot claim therapeutic effects against illness or bodily dysfunction. Their claims rest 
most often on the presence of one or several “nutraceutical” ingredients whose health benefits 
have been long recognized by nutritionists or established by scientific studies: vitamins (A, B1, 
B2, B6, PP, C, D, E), mineral salts (folic acid, calcium, magnesium, iron, iodine, etc.), 
probiotics and prebiotics, poly-unsaturated fatty acids (omega-3 and 6), and plant sterols and 
stanols. The novelty lies in the capacity and intention of industry actors to incorporate them 
into food products (dairy products, cereals, fruit juices, mineral water, etc.) or dietary 
supplements, in which they are purified, concentrated and combined in capsule, pill or liquid 
form. 
Due to their “hybrid” character, these products also occupy a position at the boundary of several 
industries and markets. Diverse actors positioned themselves in this sector in the 1990s: agro-
food companies like Danone, Unilever and Nestlé, pharmaceutical companies like Novartis and 
Sanofi, and producers of nutrients and ingredients like Arkopharma and Fenioux, which signed 
numerous tie-ups and joint ventures, with the aim of knowledge sharing in manufacturing, 
research & development, and marketing (e.g. Coca Cola and Sanofi failed commercial alliance 
in 2012 to launch “health drinks”). Facing saturated and largely glutted markets9, agro-food 
companies saw in “health” claims a way of differentiating themselves from their competition 
and “enriching” their product lines with featured attributes (“health benefits” in addition to the 
taste or nutritional advantages of the product) and higher prices (functional foods sold at prices 
2 to 7 times higher than comparable “traditional” food products). For their part, certain 
pharmaceutical companies invested in the dietary supplements sector in order to diversify their 
product lines in the context of declining innovation, major increases in the cost of research & 
development and intensifying regulatory burdens in the medicine sector.  
To justify their health claims, agro-food companies multiplied scientific guarantees and 
certifications, adopting at their own cost (albeit lower) the strategies developed by the 
pharmaceutical industry to promote medicines. Certain companies thus invested heavily in 
research & development in order to demonstrate the legitimacy of their claims. Nestlé, for 
example, had a laboratory with 3,000 researchers and devoted 1.5 billion swiss francs (1.6% of 
its operating revenue) to research in 2006; Danone, for its part, invested 130 million euros in 
its research center. These companies conducted a range of clinical trials, resembling those 
undertaken by the pharmaceutical industry on medicines, but involving more limited 
populations (from several dozens to a maximum of a hundred, as opposed to several thousand 
for medicines) and rarely respecting the protocols of double-blind randomized controlled trials. 
They could thus for the most part not lay claim to the “gold standard” represented by “evidence-
based medicine” in the world of pharmaceuticals (Timmermans and Berg, 2010; Bergeron, 
Castel and Hauray, 2015). 
These companies also tried to buttress the credibility of their claims by drawing on leading 
figures in the medical profession and scientific institutions. Thus, in 2002, the company Cema 
negotiated a partnership with the Pasteur Institute of Lille allowing them to display the 
                                                 
9 Étienne Chantrel and Pierre-Emmanuel Lecocq, “Les marges dans la filière agro-alimentaire en France,” Econo-
mie & Prévision, 3, 2009, pp. 141-149. 
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institute’s logo on the packaging of their omega 3-enriched margarine, in exchange for a 
financial contribution to the institute (which relies primarily on private-sector financing).10 In 
a similar manner, Unilever mobilized the big names in cardiology to launch its Fruit d’Or Pro-
Activ® margarine at the beginning of the 2000s.11 In another example of imitation of the 
“promotion” techniques for medicines, Unilever entered into a partnership in 2005 with the 
insurance company MAAF, in which the latter committed to reimbursing its clients for products 
branded Fruit d’Or (up to 40 euros) in exchange for having its logo appeared on the packagings. 
A similar tie-up was signed in 2006 between Danone and AGF for the reimbursement of 
purchases of Danacol®, Danone’s anti-cholesterol yogurt. Even though insurers are not 
scientific institutions, these tie-ups adopt the codes of the promotion of medicines. The 
reimbursement of products represents a kind of official recognition of evidence-based health 
benefits in European countries. 
Finally, functional foods benefitted from their position straddling different distribution 
channels, from pharmacies to supermarkets, including mail-order sales. This multiplication of 
distribution channels was often linked to a multiplication of promotion channels, ranging from 
direct advertising to the public to mobilizing pharmacists and doctors as “prescribers” of these 
products. This strategy of enlisting prescribers, relatively classic among producers of medicines 
and dietary supplements, was also adopted by food companies, like Unilever, which 
systematically peddled its products to general practitioners and cardiologists to ensure the 
development of its “Fruit d’Or” product line, and especially its “Pro-Activ” margarine, 
recommended for the treatment of high cholesterol.  
While the boom in functional foods resulted primarily in a transformation of commercial 
strategy, these products also benefitted from a favorable context for the “healthicization” of 
food in France, even if to a lesser extent than in other countries, like Japan, the United States 
and the countries of Northern Europe. The growing interest on the part of scientists and the 
media in chronic medical conditions – like cardiovascular disease, diabetes and cancer, 
presented as somehow representative of the late twentieth century – and the research of 
nutritionists like Serge Renaud and Michel de Lorgeril on the benefits of the “Cretan diet” and 
the “French paradox” contributed to putting front and center the links between food and 
cardiovascular risk. The creation of the French Food Health Safety Agency (AFSSA) in 1998, 
in the wake of the mad cow crisis (Besançon, 2010), and the implementation of the first National 
Nutrition-Health Plan in 2001, under the aegis of the ministry of health (Bossy, 2010), also 
created an institutional framework explicitly linking food and health, as much in the regulation 
of the agro-food sector as in the consumer information campaigns (e.g. the “Eat-Move” 
program) of the French Institute for the Promotion of Health (INPES)). This media and 
institutional context promoted and supported rising consumer interest in products that 
highlighted their benefits (healthy foods) or absence of risks (light or organic foods, for 
example) for health. Although the first “individual survey on food consumption” (INCA), 
published by AFSSA in 1999, did not include a section on “healthy foods” and dietary 
supplements, the second one, conducted from 2006 to 2007, showed that nearly 20% of 
surveyed adults (and 12% of children) had consumed at least one dietary supplement over the 
                                                 
10 Catherine Petitnicolas, “Le logo de Pasteur Lille apposé sur une margarine,” Le Figaro, 8 March 2002. 
11 Jean-François Arnaud, “Fruit d’Or invente la margarine qui se vend à prix d’or,” Le Figaro, 6 May 2002. 
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course of the previous year, and more than 11% (4% of children) over the course of the 7-day 
study.12 Furthermore, 60% of surveyed households (15% “always”, 45% “sometimes”) said 
they favored foods that indicated nutritional or health benefits on their label. 
At the end of the 1990s, these industrial strategies ran up against two kinds of uncertainties, 
which represented obstacles to the sustainability of the market. The first dealt with the 
regulatory status and the health advantages of functional foods. Should they be considered like 
medicines, like “enriched” foods, or as distinct products with their own classification? And how 
can one guarantee that these products indeed provide the health benefits they claim and, on the 
other hand, do not present risks that might be commensurate with these benefits? If this 
uncertainty about the regulatory status and health advantages of the products had enabled their 
development, in allowing industry actors to promote them “at the lowest cost,” they also 
represented a danger in exposing these same industry actors to regulatory interventions (from 
the French Administration of Consumption, Competition and Fraud Repression (DGCCRF), 
the Medicines and Food Agencies) or litigation by consumer organizations. Furthermore, 
industry actors experienced considerable difficulties in making their product lines sustainable 
and maintaining high prices based on claims that did not enjoy any official recognition. 
A second uncertainty had to do with the commercial status and value of these products. An 
initial difficulty concerned their commercial positioning: Should they be distributed in 
pharmacies, parapharmacies, small or large supermarkets? Should they be placed in a specific 
“functional foods” section, or with other foods with no health benefits? Should they be 
promoted directly to the consumer through advertising, or via prescribers (doctors, 
pharmacists)? One may illustrate these issues with the commercial failure of certain products 
like the health drink Nesfluid®, because distributors and consumers failed to situate it between 
the “fruit juice”, “fresh snacks”, and “health and dietetic” sections and because it was priced 
well above other products in these sections.13 Yet another difficulty involved competition 
between industry actors. As the claims born by these products did not benefit from any 
protections (in the form of a patent, certification, or exclusive claim) or market entry barrier 
(marketing authorization), they risked being copied at any time and low cost.Thus, throughout 
the 2000s, functional foods appeared as products under retailer's brand, making the same claims 
to health benefits but sold at lower price points14. Major agro-food companies became strong 
supporters of European regulation and evaluation of health benefits, because they saw it as a 
means of “disciplining the competition” (Stanziani, 2005). In obtaining certification of their 
claims by French and European health agencies, these companies hoped to thereby erect a 
barrier to market entry for their competitors, to justify their higher prices and thus finance their 
research efforts. 
From the end of the 1990s to the middle of the 2000s, various initiatives were proposed by 
industry actors, consumer organizations, and regulatory authorities with the goal of clarifying 
                                                 
12 Agence française de sécurité sanitaire des aliments (AFSSA), Etude individuelle nationale des consommations 
alimentaires 2 (INCA 2), September 2009. [https://www.anses.fr/fr/system/files/PASER-Ra-INCA2.pdf]  
13 http://www.lsa-conso.fr/nesfluid-une-chute-annoncee,124599  
14  Jean-François Arnaud, « Carrefour clone Actimel », Le Figaro, 7 octobre 2002.  
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the status of these boundary products in order to regulate the interstitial markets on which they 
circulated. 
II. Boundary work: the frustrated institutionalization of the functional 
foods market  
The appearance of functional foods in the middle of the 1990s greatly contributed to a blurring 
of the boundary between the markets for medicine and for food, chipping away at it from both 
sides. The ambiguity surrounding the regulatory status and health merits of these products 
undoubtedly contributed to their success in the 1990s. But it was also the cause of numerous 
controversies between industry actors, consumer organizations and regulatory authorities, 
which greatly complicated their establishing a sustainable position on the market. From the 
mid-1990s, these various actors engaged in considerable “boundary work” to redraw the 
boundaries between medicine and food. The concept of “boundary-work” has been developed 
by Thomas Gieryn to think about the ways in which scientists attempt to attribute “selected 
characteristics to the institution of science (i.e. to its practitioners, methods, stock of knowledge, 
values and work organization) for purposes of constructing a social boundary that distinguishes 
some intellectual activities as ‘non-science’” (Gieryn, 1983, p.782). As with the scientists 
Gieryn studied, regulatory authorities and industry actors undertook a project of codification 
and evaluation so as to be able to distinguish medicines, intended to treat and prevent illness, 
from food products (and supplements), intended to maintain good health and to act against the 
risk of illness. This work of setting boundaries was the source of intense controversy. It created 
new “territorial divisions” and new interstitial zones straddling these different domains. On the 
other hand, one also witnessed a convergence of modes of evaluation and thus of demonstration 
of health benefits and risks associated with medicines and food, leading industry actors to 
reconsider their research & development and marketing strategies. In what follows, we will 
therefore first present an analysis of this boundary work, with an initial focus on the new modes 
of regulation of functional foods put in place over the period from 2000 to 2006 We will then 
turn to the modes of evaluation of product health benefits by the AFSSA and the EFSA, before 
concluding with a discussion of the strategies developed by companies for responding to this 
new regulation. 
2.1.  A (re)composition of regulatory boundaries 
Regulation of functional foods stirred considerable controversy among public authorities and 
industry actors. The issue was whether to maintain (even if it meant altering) the regulatory 
boundary between the two and situate these products on one side or the other, or to erect new 
boundaries and construct an ad hoc commercial space by defining new categories for these 
products. There were thus multiple initiatives in the 1990s and 2000s coming from both public 
and private actors, both French and European, seeking to redefine product categories and 
regulatory modes. 
The first option envisaged by public authorities consisted in simply applying existing 
regulation. According to the provisions of the Public Health Code, all products other than 
medicines claiming “preventative or curative properties in relation to illness” or “to restore, 
correct or modify bodily functions,” must submit an application to the Medicines Agency 
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(AFSSAPS) for a “product advertising” visa (PP visa), describing the proposed advertising 
campaign as well as the grounds for the properties being claimed (Veyssière, 2007). A 
commission of the AFSSAPS would then rule within 30 days on the merits of the claims with 
regard to the law and their scientific basis, after possibly consulting with the Food Agency 
(AFSSA). Food products also fall within the Consumption Code, article L.121-1 of which 
prohibits all false advertising to the consumer. Oversight of claims was thus entrusted to the 
French Administration for Consumption, Competition and Fraud Repression (DGCCRF), who 
could then solicit a scientific opinion from the AFSSA and, in the event of an infringement, 
prohibit the advertising campaign or impose a fine on the company. In addition, consumer 
organizations could refer a case to the DGCCRF or bring a legal action against the company 
for false advertising (Veyssière, 2007). In cases of “boundary products,” where there was a 
doubt as to whether to classify the product as food or medicine, the product in question had to 
be submitted to the regulatory procedure for medicines, in line with the European Directive 
2001/83/CE of 6 November 2001. 
Although the boundary between medicine and food was clearly delineated by the law, it did not 
resolve the uncertainty surrounding the status of functional foods in the 1990s. As Laurence 
Veyssière (2007) has observed, there were very few applications for PP visas submitted by 
companies selling supplements or food products with health claims. But consumer 
organizations, and in particular the UFC-Que Choisir, brought several law suits against these 
companies for “false advertising.” Indeed, these companies used vague terms to suggest 
benefits for well-being or prevention without explicitly falling within the legal definition of 
medicines. In spite of this strategy, numerous judgments led to the reclassification of these 
products as medicines by presentation (and more rarely by function) and convicted their 
producers of illegal pharmacy practices, selling of medicines without marketing authorization 
(AMM), and illegal advertising for medicines (Sevaux, 2014).  Clearly, the uncertainty 
surrounding the regulatory status of functional foods offered companies a useful framework for 
innovation in advertising but also exposed them to considerable legal risk. However, this 
uncertainty surrounding the legal and regulatory classification of functional foods also 
constituted a major difficulty for regulatory authorities, whose mandate to control and sanction 
did not rest on precise categories for classifying these boundary products, at the very moment 
of their proliferation.  
The solution adopted by French, and later European, regulatory authorities consisted in 
reconstructing the boundary between claims made by two types of products, medicines and 
foods. As seen above, all products that claim “preventative or curative properties in relation to 
illness” or “to restore, correct or modify bodily functions” are considered medicines. 
Throughout the 1990s, commissions of experts, representatives of public authorities and 
industry actors tried to specify precisely what claims could be made by foods without falling 
under this definition of a medicine. The first of these to be subject to attempts at definition in 
France and Europe were nutritional claims. They were defined by the decree of 27 September 
1993 as “all representations and advertisements that state, suggest or imply that a food product 
possesses particular nutritional properties, either by virtue of the energy (caloric value) that it 
provides or does not provide, or that it provides at a reduced or elevated level, or by virtue of 
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the nutrients it contains or does not contain, or contains in reduced or elevated amounts.”15 
Based on this decree, the Inter-ministerial Committee for studying foods with specific diet 
purposes (CEDAP) proposed, in a notice issued on 18 December 1996, a list of nutrients and 
labelling that could be used by companies in their advertisements without requiring a PP visa.16 
This list was primarily comprised of vitamins and mineral salts whose effects on the normal 
functioning of the body had long been established by nutritionists. 
Based on this determination, industry actors and scientists tried to erode the boundary 
established with medicines and extend as much as possible the spectrum of possible claims that 
could be made for foods. At the end of the 1990s, the European projects FUFOSE (Functional 
Food Science in Europe)17 and then PASSCLAIM (Process for the Assessment of Scientific 
Support for Claims on Foods) – coordinated by the International Life Sciences Institute (ILSI), 
a consortium of scientists and industry actors, and financed by the European Commission – 
generated the following definition of a functional food: “Similar in appearance to a 
conventional food, a functional food is demonstrated to have physiological benefits and/or to 
reduce the risk of chronic disease beyond basic nutritional functions.” Two different claims – 
“improving function” and “reducing risk of illness” – were suggested. The first challenged the 
monopoly of medicines in the maintenance, restoration and improvement of bodily functions. 
The second aimed to establish a new boundary between curative claims (acting on illness), 
falling within the exclusive domain of medicine, and preventive claims (acting on the risk of 
illness), which might also be made by food products or supplements. 
This work culminated in the European Regulation 1924-2006 of 20 December 2006 “on 
nutritional and health claims made on foods.”18 Justified in terms of the need to harmonize the 
functioning of the internal market, to promote innovation and protect consumers, this regulation 
defines acceptable claims and their mode of regulation at the European level. It defines three 
types of claims:  
1. Nutritional claims, which are defined in the same terms as the French decree of 1993: 
“any message that states, suggests or implies that a food has particular beneficial 
nutritional properties”;  
2. Health claims: “any message that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health”. Health claims are 
themselves divided into two groups: 
2.1 Reduction of risk of illness claims: “any health claim that states, suggests or implies 
that the consumption of a food category, a food or one of its constituents 
significantly reduces a risk factor in the development of a human disease”;  
2.2 Functional claims: “the role of a nutrient or other substance in the growth, 
development and functions of the body; or psychological and behavioral functions; 
or […] slimming or weight-control or a reduction in the sense of hunger or an 
                                                 
15 https://www.legifrance.gouv.fr/affichTexte.do?cidTexte=LEGITEXT000006082742 
16 “Avis du 18 décembre 1996 sur les recommandations relatives au caractère non trompeur des allégations nutri-
tionnelles fonctionnelles”, Bulletin officiel de la concurrence, de la consommation et de la répression des fraudes, 
n° 97/17, p. 730. 
17 http://www.ilsi.org/Europe/Pages/FUFOSE.aspx  
18 https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32006R1924&from=en  
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increase in the sense of satiety or to the reduction of the available energy from the 
diet”.  
Thus, the regulation created a new boundary between foods and medicines, having essentially 
to do with the kinds of claims made by the products: with medicines comprising any product 
claiming a curative effect on illness or on bodily dysfunction; and healthy foods and dietary 
supplements including any product claiming a preventive effect (on the risk of illness) or an 
effect on the maintenance or development of bodily functions.  
The regulation also initiated a procedure for evaluating these health benefits. It assigned to the 
European Food Safety Authority (EFSA) the role of studying and issuing opinions on the 
scientific bases for all claims submitted by member states. Based on these opinions, the 
European Parliament was to adopt, by 2010, a positive list of all the nutritional and health claims 
that could be used by industry actors in the advertising and packaging of their products. Any 
claim not appearing on this list would be prohibited. 
Even while creating a boundary between the claims made by medicines and those made by 
foods, the regulation established a procedure that tended to cause the modes of evaluation of 
both products to converge. From this point on, the claims made for products by industry actors 
would be made to conform, in advance, by scientific assessments conducted by a health 
authority: the EMA (or the AFSSAPS in France) for medicines, the EFSA (or the AFSSA in 
France) for foods.  
2.2.  A (re)evaluation of health benefits and risks 
The uncertainties raised by the appearance of functional foods did not only have to do with their 
regulatory status but also more generally with their health benefits. As the markets developed, 
it appeared increasingly necessary in the eyes of various actors to evaluate the legitimacy of 
these claims. For French and European public authorities, it was about protecting the heath of 
consumers who might be encouraged to consume these products in excessive quantities or 
instead of medicines, but also a matter of promoting innovation and regulating competition 
while avoiding the “inflation” of “fantastic” and “unfounded” claims. For industry actors, it 
was an issue of protecting themselves from legal action for false advertising, making credible 
their health claims to consumers, and justifying considerably higher prices for these products. 
Thus, Unilever used the European procedure for “novel foods” – which submits market 
authorization for new food ingredients to clinical testing to assess any possible health risks19 – 
as a way of establishing recognition of the significant benefits of plant sterols in the reduction 
of “bad” cholesterol. Requests for the evaluation of health benefits on the part of agro-food 
companies also served as a means of protecting themselves from the risk of lawsuits brought 
by consumer organizations. This was for example the case with Danone, who responded to the 
threat of legal action for “false advertising” made by the French Confederation of Housing and 
Living Conditions (CLCV), a consumer group, by submitting a request to the DGCCRF in 2002 
to verify the ten claims made on the label of its yogurt drink, Actimel®, which was ultimately 
done by the AFSSA in 2004. Conversely, a lawsuit filed by the UFC-Que Choisir organization 
                                                 
19 https://ec.europa.eu/food/safety/novel_food/authorisations_en  
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(another consumer group) against MAAF (an insurance company), challenging the advertising 
campaign announcing the partnership between the insurer and Unilever for the reimbursement 
of the latter’s Fruit d’Or Pro-activ® margarine, was rejected by the Court on the grounds that 
the campaign “clearly specified that the product line enriched with plant sterols markedly 
reduced bad cholesterol when consumed as part of an appropriate, fruit-rich diet.”20 More 
broadly, some large agro-food companies were strong supporters of the implementation of 
European regulation and evaluation procedures for health claims, seeing it as a means of 
eliminating products and companies whose claims were not based on scientific evidence and 
considerable investment in clinical research. Main French retailers developed throughout the 
2000s their own functional foods labeled under their retailer brand, making the same claims to 
health benefits but sold at lower prices.21 By obtaining validation for their claims from French 
and European health agencies, these companies hoped to thus erect a barrier to entry for their 
competitors. 
These private interests converged in part with the desire of health authorities and consumer 
organizations to control a nascent market whose effects on public health appeared mixed. Since 
its creation in 1999, the AFSSA has been charged with evaluating both the nutritional and 
toxicity risks as well as nutritional, functional and health claims of functional foods. This 
mission was undertaken internally by a “nutrition” committee of specialized experts (CES), 
which itself combined committees that had previously been located within the French Higher 
Council for Public Hygiene (CSHPF) and the CEDAP. The agency conducted individual 
analyses of products at the request of the DGCCRF or the company concerned. More broadly, 
it sought to establish guidelines for industry actors to assist them in preparing applications in 
anticipation of the implementation of a European evaluation procedure by the EFSA. Between 
2000 and 2008, 590 claims were evaluated, with 20% receiving a favorable opinion from the 
AFSSA. And in 2006, the experts of the “Human Nutrition” CES relied on these evaluations to 
formulate guidelines for industry actors for the constitution and evaluation of their applications 
dealing with nutritional and health claims for their food products. 
An analysis of AFSSA opinions on product health claims as well as the guidelines published in 
2006 sheds light on the challenges of this evaluation. The first challenge concerned 
demonstration of the benefits of the food or nutrient. Numerous claims were rejected by the 
AFSSA due to an insufficient characterization or demonstration of the causal link between the 
nutrient and the claimed health effect. Taking the example of probiotics, the committee 
repeatedly questioned the concept of “good” and “bad” intestinal flora as well as the links 
between the properties (live or dead bacteria, family or specific strain of bacteria), the amount 
of bacteria and their effects on intestinal flora. The AFSSA rejected the claim “probiotic good 
for the intestine” made for a dietetic food product containing a probiotic, intended for infants 
and young children with risk of lactose allergies. If the first opinion (2004) had insisted on the 
absence of a demonstrated clinical effect, the second one (2007) underscored again the lack of 
comparative clinical studies (with the same product, but without the probiotic) and the claim 
was thus rejected as “imprecise” and scientifically “not proven.” When the Afssa evaluated the 
                                                 
20 “Feu vert du TGI pour la pub anticholestérol,” Ouest France, 14 June 2006, Factiva Stérols, p. 96. 
21 Jean-François Arnaud, « Carrefour clone Actimel », Le Figaro, 7 octobre 2002.  
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ten claims proposed by Danone for its Actimel® product in 2004, it recognized that the strain 
might have beneficial health effects, but that the scientific evidence adduced was insufficient 
to demonstrate all the claimed effects (insufficient number of subjects in the clinical trials, study 
subjects who did not correspond to targeted population, ill adapted product dose, etc.). 
The second issue concerned the articulation between the benefits and risks of the products. 
Unlike medicines, whose risks are acceptable as long as they are counterbalanced by significant 
therapeutic benefits against serious illness, foods are defined, first and foremost, by their 
absence of risk, with any consideration of health benefits being secondary. It was for this reason 
that the European regulation of 2006 subjected the acceptance of these claims to an evaluation 
of the nutritional profile of the products. In the same way, the AFSSA proceeded to the 
systematic evaluation of health and nutritional risks of food products. At a basic level, the 
committee ensured that the nutrient or food bearing the claim did not constitute any risk to 
health or of interaction with other foods. In the case of probiotics, companies were 
systematically asked to demonstrate, based on the literature or preclinical or clinical trials, the 
absence of any danger from the strains. At a second level, the product itself – in terms of dosage 
– must integrate into a normal daily diet and its components must respect the nutritional profile 
of products of the same type. Any health benefits depend, of course, on the quantity of the 
substance said to be beneficial, but also on the recommended amount of this substance and of 
the food product in the recommended dietary allowances. The AFSSA and the AFSSAPS also 
established maximum doses of nutrients above which the product passes from the domain of 
food to that of medicine. Thus, in a 2008 opinion on the evaluation of the scientific basis for 
claims related to cerebral functioning, memory and vision for an omega-3-enriched dietetic 
margarine, used for spreading or cooking, the agency issued a favorable response for the claim 
“omega-3s contribute to the sound functioning of the cardiovascular system,” on the condition 
that the applicant respect “a quantity of omega-3 fatty acids for 100g of product greater than or 
equal to 15% of the Recommended Dietary Allowance (RDA) for an adult man; a ratio of alpha-
linolenic acid (ALA) below or equal to 5; and a total lipid composition in accordance with 
recommendations for the prevention of heart disease.” Finally, at yet another level, the AFSSA 
incorporated consideration of the population targeted by the claims. Same claims made for 
biscuits received a negative opinion for children, because they could contribute to childhood 
obesity, and a positive one for seniors. 
A third issue, directly linked to the second, concerns the formulation of the claim by the 
company. Once information became the central element of the regulation (Frohlich, 2017), the 
conflict around the boundary between medicine and food was in effect largely displaced onto 
the choice of terms likely to be endorsed by both industry actors and regulatory authorities. For 
the Food Agency, a product claim should not lead to unbalanced dietary behavior 
(overconsumption of the product, underconsumption of others) and the company should take 
care to indicate that the food should be consumed as part of a balanced diet. Likewise, the claim 
should not promote “unsuitable” behavior on the part of individuals who consume a food (or 
dietary supplement) instead of a medicine to treat their illness, putting at risk their chances of 
recovery. This was the reason for the rejection in 2001 of a claim – “part of a diet for elevated 
cholesterol” – for an oil with a certified quantity of vitamin E and rich in omega-3 fatty acids 
aimed at people with hypercholesterolemia or risk of heart disease. In the case of Actimel®, 
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the AFSSA rejected nine of the ten claims submitted by Danone22 and proposed “participates 
in the strengthening of natural bodily defenses” instead of “helps to strengthen natural 
defenses,” even while requiring that the label specified that “the expected beneficial effects are 
only scientifically proven while the product is being consumed and cease very quickly after 
stopping.” Behind these modifications, which may seem minor at first, we see precisely the 
boundary work being carried out by the AFSSA.  In substituting the term “participates” for the 
term “helps,” the agency wanted to insist not only on the limited effect of the product in the 
prevention of illness but also to neutralize any risk that this product might be substituted for a 
balanced diet (when maintaining “normal bodily function”), or for a medicinal treatment (when 
treating an illness that has already taken hold).  
From 2006, the EFSA commission responsible for the evaluation of nutritional and health 
claims recruited a number of experts from the AFSSA and was to a large extent inspired by the 
criteria developed by that agency for evaluating claims. Like its French counterpart, the EFSA 
revealed itself to be particularly demanding, since only 510 claims out of 2,758 (created through 
the consolidation of nearly 40,000 applications submitted by member states) received positive 
opinions at the end of the evaluation process in 2010. As for probiotics, the EFSA rejected all 
39 applications. Danone decided to withdraw its application in the middle of the EFSA 
procedure rather than risk a negative response. 
These decisions slammed the brakes on the development of functional foods in Europe, to the 
astonishment of the companies that had invested in the sector. As the EFSA adopted methods 
and criteria of evaluation for functional foods that were as demanding as those adopted by its 
counterpart in charge of medicines (EMA) for their market authorization, was it still worth 
proposing claims for food products? 
2.3.  A (re)organization of markets and commercial strategies  
While many industry actors had been in favor of a European evaluation procedure for health 
benefits, the EFSA’s very severe responses to the vast majority of applications constituted a 
veritable bolt from the blue. This was particularly the case for probiotic companies who saw all 
of their claims rejected. We will now conclude our analysis by exploring the influence of these 
evaluations on the reorganization of the commercial strategies and markets for functional foods 
since the implementation of the European Regulation of 2006. 
The case of dairy products enriched with probiotics – Danone’s Activia® and Actimel® – 
illustrates the strong links between the possibility for a company to make claims for its products 
and its ability to thereby promote these products. Whereas an article in the newspaper 
Libération, on 24 March 2004, considered that the opinion of AFSSA rejecting nine of ten 
claims constituted a humiliation for Danone, the company’s spokesperson, Corinne Robin, 
declared the opposite: “The claim of natural defenses, the one we have used since the beginning, 
                                                 
22 The nine rejected claims were as follows: “helps to strengthen your intestinal barrier”, “helps to regulate the 
immune system”, “contributes to the proper functioning of the immune system”, “helps to strengthen the intestinal 
immune system”, “helps the body to defend itself effectively”, “contributes to making the body more resistant”, 
“helps to protect your body”, “helps your intestines reject certain undesirable bacteria”, “helps your body fight 
against daily attacks”. 
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was accepted as the most pertinent. This decision grants for the first time the status of probiotic 
for a mass consumption product.”23 Indeed, the company turned this claim into the basis for the 
promotion of Actimel®. And the AFSSA’s positive opinion, even if it came with numerous 
reservations, greatly contributed to legitimating this claim. Danone’s 2004 sales of Actimel® 
in France were 111 million euros (a 50% increase) and 285 million euros (+14%) for 
Bio®/Activia®. Sales for these two products saw considerable growth in France, and even more 
so globally, with Actimel® going from 890 million euros globally in 2006 to 1.2 billion in 
2009, and Activia® going from 1.3 billion euros in 2006 to 2.6 billion in 2009 (with annual 
growth for the two products ranging from 10% to 20%). However, after withdrawing its 
applications to the EFSA for claim recognition for both products in 2010, Danone was no longer 
in a position to make any health claims. Even though the company tried to preserve the 
association of these products with health benefits, playing on certain elements of their 
marketing (the downward arrow on the packaging for Activia® suggesting effects for digestion, 
and the advertising associating the consumption of Actimel® with the arrival of winter), the 
brands registered a steady decline in sales, with the figures for Activia® declining from 2.9 
billion in 2012 to 2.4 billion in 2014, and those for Actimel® dropping by 17% in France 
between 2013 and 2014.24  
The situation was markedly different for dietary supplements. If many failed to receive approval 
from the European authority for their health claims, their sales were not as strongly affected by 
these decisions as were those for food products. If we are to believe the figures reported by the 
association of dietary supplement producers (Synadiet), sales slid between 2008 and 2010, but 
then returned to growth from 2011, with average annual increases of 3% to 4% between 2011 
and 2016. The Synadiet reports sales figures for each market segment (from diet pills to immune 
defenses, including beauty products, constipation, respiratory tract and pregnancy). It is thus 
not possible to precisely measure the effect of the (non-) recognition of claims on sales based 
on this data. It is worth noting, however, that the two segments – “constipation/digestion” and 
“immune defenses” – in which some products contain probiotics and prebiotics (whose claims 
were all rejected by the EFSA) experienced divergent trajectories, with the sales for the former 
showing considerable growth and those for the latter collapsing. 
The market for supplements would thus seem to have been less affected by regulation than that 
for food products. Indeed, the industry actors in this sector deployed a series of strategies to 
counterbalance the potentially harmful effects of EFSA regulation on the marketing of their 
products. A first strategy consisted in associating the “nutrients” whose claims were rejected 
by the EFSA with others (e.g. vitamins), which bore claims recognized by the EFSA and close 
to those promoted by the producers (e.g. muscle tone or protection against winter illnesses). A 
second strategy, which complemented the first, entailed promoting the “health benefits” of their 
products with doctors and pharmacists rather than directly to consumers. Indeed, the European 
Regulation of 2006 applied only to claims made directly to consumers and thus left outside its 
purview the interactions between industry actors and healthcare professionals, as well as those 
between healthcare professionals and patients/consumers. 
                                                 
23 http://www.lsa-conso.fr/actimel-ne-convainc-pas-l-AFSSA,78167 
24 http://www.capital.fr/entreprises-marches/danone-ses-yaourts-sante-n-ont-plus-la-forme-967287  
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More generally, however, the companies that had invested in the functional foods sector were 
made to rethink their research & development and marketing strategies. The regulatory division 
of labor between the European Medicines Agency and the EFSA was mirrored in the division 
of labor of certain companies (primarily from the agro-food industry), between those which 
continued to hope to be able to modify the evaluation criteria and the opinions of the EFSA on 
health claims, and others that considered the EFSA opinions to have definitively blocked the 
institutionalization of a healthy foods market and decided to turn to the European Medicines 
Agency. Producers of supplements and ingredients seemed to still hesitate between the two 
strategies and thus participated in meetings and conferences organized by these two groups of 
producers. Far from completed, the boundary work of regulatory authorities and industry actors 
seems to have only just begun. 
Conclusion 
Two major conclusions emerge from this study of the formation of a market for functional foods 
in France and Europe at the end of the twentieth century. 
The first brings us to a reconsideration of the now classic works in the sociology and history of 
quality that we presented in the introduction. We rediscover a certain number of conclusions 
from these works concerning the importance of processes of classification in the reduction of 
commercial uncertainty and the disciplining of competition. Thus, the rise and fall of the 
functional foods markets is explained in large part by the high degree of uncertainty on the part 
of consumers, industry actors and regulatory authorities with regard to the health qualities of 
these products, and the incapacity of these different actors to distinguish “good” from “bad” 
functional foods. In rejecting the overwhelming majority of claims presented by companies, the 
French and European regulatory authorities not only brought “discredit” upon the health virtues 
of these products, but they also modified the terms of the competition between companies by 
greatly increasing the cost of market entry. However, our research brings to light a second level 
of uncertainty presented by the functional foods themselves, concerning their own status. The 
challenge for public authorities, industry actors and consumers was, in effect, to rethink the 
established boundary between medicine and food, and more generally between sickness and 
health, treatment and prevention. Drawing on the typology established by Armand Hatchuel 
(1995), the challenge for these actors was not only to sort good from bad functional foods 
(factual uncertainty) but to rethink this category of products and, through this process, redefine 
the boundary between medicine and food, sickness and health, treatment and prevention 
(notional uncertainty). Accordingly, our research constitutes a contribution to a sociology of 
commercial innovation, by showing the importance of boundary work in the classification of 
products and the structuration of the market. 
A second major conclusion of this research involves the dynamic articulation between two 
processes: the commoditization of health and the healthicization of commerce. At first pass, the 
history of functional foods can be read as a process of commoditization of health, leading 
companies to instrumentalize the value accorded by our societies to health in order to “enrich” 
their food products by highlighting a distinctive quality (“health benefits”), thereby justifying 
higher prices and distinguishing them from their competition. According to this approach, the 
highlighting of the health virtues of products by companies is the extension (and flipside) of the 
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processes which, throughout the twentieth century, had led to the increasingly robust regulation 
of health risks linked to food and to the recent discovery of the influence of food on the most 
emblematic chronic illnesses of the late twentieth century (cardiovascular diseases, obesity, 
cancer, etc.). Another reading, complementary to the first, consists in seeing the formation of 
this market as the consequence of a strengthening of the regulation of the medicine market 
around a curative logic and evidence-based medicine. According to this logic, the functional 
foods market would constitute a space of “reclassification” for products not situated in the 
curative field or not satisfying the criteria of evidence-based medicine. This approach in terms 
of commoditization of health clearly illuminates the importance of the commercial marketing 
strategies that presided over the genesis of the functional foods market through the 1990s. 
However, in order to grasp the second part of this history, centered around the regulation of 
nutritional and health claims by food safety authorities from the 2000s, it seems to us crucial to 
invert the perspective and instead explore the process of healthicization of the market, along 
two interrelated lines. First, in regulating nutritional and health claims indicated on package 
labels or in advertising to consumers, this policy made the market into a mechanism for the 
promotion and extension of public health (Frohlich, 2017). Second, in applying to food (and 
dietary supplements) the evaluation framework developed for medicines (and based essentially 
on the evidence-based evaluation of a balance between health benefits and risks), this policy 
extended regulation from a curative approach to a public health approach, conceived by the 
World Health Organization as “a state of complete physical, mental and social well-being.” 
Even though they correspond to different moments in the history of the functional foods market, 
these two processes are intertwined in a dialectic, the endpoint of which, still uncertain, is 
central to the institutionalization of the functional foods market.25  
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